Publication:
Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells

Simple item page
dc.contributor.authorThomas F. Allisonen_US
dc.contributor.authorPeter W. Andrewsen_US
dc.contributor.authorYishai Avioren_US
dc.contributor.authorIvana Barbaricen_US
dc.contributor.authorNissim Benvenistyen_US
dc.contributor.authorChristoph Bocken_US
dc.contributor.authorJennifer Brehmen_US
dc.contributor.authorOliver Brüstleen_US
dc.contributor.authorIvan Damjanoven_US
dc.contributor.authorAndrew Elefantyen_US
dc.contributor.authorDaniel Felkneren_US
dc.contributor.authorPaul J. Gokhaleen_US
dc.contributor.authorFlorian Halbritteren_US
dc.contributor.authorLyn E. Healyen_US
dc.contributor.authorTim X. Huen_US
dc.contributor.authorBarbara B. Knowlesen_US
dc.contributor.authorJeanne F. Loringen_US
dc.contributor.authorTenneille E. Ludwigen_US
dc.contributor.authorRobyn Mayberryen_US
dc.contributor.authorSuzanne Micallefen_US
dc.contributor.authorJameelah S. Mohameden_US
dc.contributor.authorFranz Josef Mülleren_US
dc.contributor.authorChristine L. Mummeryen_US
dc.contributor.authorNorio Nakatsujien_US
dc.contributor.authorElizabeth S. Ngen_US
dc.contributor.authorSteve K.W. Ohen_US
dc.contributor.authorOrla O'Sheaen_US
dc.contributor.authorMartin F. Peraen_US
dc.contributor.authorBenjamin Reubinoffen_US
dc.contributor.authorPaul Robsonen_US
dc.contributor.authorJanet Rossanten_US
dc.contributor.authorBernhard M. Schuldten_US
dc.contributor.authorDavor Solteren_US
dc.contributor.authorKoula Sourrisen_US
dc.contributor.authorGlyn Staceyen_US
dc.contributor.authorEdouard G. Stanleyen_US
dc.contributor.authorHirofumi Suemorien_US
dc.contributor.authorKazutoshi Takahashien_US
dc.contributor.authorShinya Yamanakaen_US
dc.contributor.otherA-Star, Bioprocessing Technology Instituteen_US
dc.contributor.otherThe Florey Institute of Neuroscience and Mental Healthen_US
dc.contributor.otherThe Francis Crick Instituteen_US
dc.contributor.otherWiCell Research Instituteen_US
dc.contributor.otherA-Star, Genome Institute of Singaporeen_US
dc.contributor.otherMax Planck Institute for Molecular Geneticsen_US
dc.contributor.otherHospital for Sick Children University of Torontoen_US
dc.contributor.otherUniversity of Kansas, School of Medicineen_US
dc.contributor.otherWalter and Eliza Hall Institute of Medical Researchen_US
dc.contributor.otherUniversity of Melbourneen_US
dc.contributor.otherRoyal Children's Hospital, Melbourneen_US
dc.contributor.otherGladstone Institute of Cardiovascular Diseaseen_US
dc.contributor.otherMonash Universityen_US
dc.contributor.otherUniversity of Torontoen_US
dc.contributor.otherLeiden University Medical Center - LUMCen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherMedizinische Universitat Wienen_US
dc.contributor.otherKyoto Universityen_US
dc.contributor.otherJackson Laboratoryen_US
dc.contributor.otherHebrew University of Jerusalemen_US
dc.contributor.otherUniversität Bonnen_US
dc.contributor.otherScripps Research Instituteen_US
dc.contributor.otherAdministrative Headquarters of the Max Planck Societyen_US
dc.contributor.otherUniversitätsklinikum Schleswig-Holstein Campus Kielen_US
dc.contributor.otherDavid Geffen School of Medicine at UCLAen_US
dc.contributor.otherOsterreichische Akademie Der Wissenschaftenen_US
dc.contributor.otherUniversity of Sheffielden_US
dc.contributor.otherNational Institute for Biological Standards and Controlen_US
dc.contributor.otherMax Planck Institut für Informatiken_US
dc.contributor.otherUniversity of Connecticut Health Centeren_US
dc.contributor.otherHadassah University Medical Centreen_US
dc.contributor.otherInternational Stem Cell Banking Initiativeen_US
dc.contributor.otherJackson Laboratory for Genomic Medicineen_US
dc.date.accessioned2019-08-23T10:25:40Z
dc.date.available2019-08-23T10:25:40Z
dc.date.issued2018-12-01en_US
dc.description.abstract© 2018 The Author(s). The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC's malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment of pluripotency and malignant potential, which are both relevant to the pre-clinical safety assessment of PSCs.en_US
dc.identifier.citationNature Communications. Vol.9, No.1 (2018)en_US
dc.identifier.doi10.1038/s41467-018-04011-3en_US
dc.identifier.issn20411723en_US
dc.identifier.other2-s2.0-85047190636en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/44994
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047190636&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectChemistryen_US
dc.subjectPhysics and Astronomyen_US
dc.titleAssessment of established techniques to determine developmental and malignant potential of human pluripotent stem cellsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047190636&origin=inwarden_US

Files

Collections

Scopus 2018